Send me a link:

*Text messaging rates may apply.

 Dow Down0.19% Nasdaq Up0.45%

Ligand Pharmaceuticals Incorporated (LGND)

-NasdaqGM
51.17 0.08(0.16%) Jul 30, 3:59PM EDT
ProfileGet Profile for:
Ligand Pharmaceuticals Incorporated
11119 North Torrey Pines Road
Suite 200
La Jolla, CA 92037
United States - Map
Phone: 858-550-7500
Website: http://www.ligand.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:20

Business Summary 

Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. Its late-stage development programs include Promacta, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Captisol-enabled Melphalan IV for the multiple myeloma transplant setting; Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis; and Nexterone, an injectable formulation. The company’s late-stage development programs that are in Phase III clinical trials comprise Captisol-enabled Noxafil-IV; MK-8931 Beta-Secretase Inhibitor program for the treatment of Alzheimer’s disease; Captisol-enabled Carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings; and Captisol-enabled Delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections. It also offers Sparsentan that is in Phase II clinical trials for kidney diseases; Lasofoxifene, an estrogen partial agonist for osteoporosis treatment and other diseases; and Captisol-enabled Topiramate Injection, which is in Phase I clinical trials for the treatment of partial onset or primary generalized tonic-clonic seizures. In addition, the company’s preclinical stage products include HepDirect for liver diseases; Oral Human Granulocyte Colony Stimulating Factor for the treatment of Neutropenia; and IRAK4 Inhibitor for inflammation. Further, it provides Glucagon Receptor Antagonist that is in Phase I clinical trials for diabetes; Selective Androgen Receptor Modulator, which is in Phase II clinical trials for the therapeutic benefits; and Captisol-Enabled Clopidogrel that is in Phase III clinical trials for anti-coagulants. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Ligand Pharmaceuticals Incorporated

Corporate Governance 
Ligand Pharmaceuticals Incorporated’s ISS Governance QuickScore as of Jul 1, 2014 is 9. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 9; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. John L. Higgins , 44
Chief Exec. Officer, Pres and Exec. Director
878.00K382.00K
Dr. Nishan DeSilva M.D., 41
Chief Financial Officer and VP of Fin. & Strategy
391.00K0.00
Mr. Matthew W. Foehr , 41
Chief Operating Officer and Exec. VP
554.00K260.00K
Mr. Charles S. Berkman J.D., 45
VP, Gen. Counsel and Sec.
399.00K1.74M
Ms. Melanie J. Herman , 35
Principal Accounting Officer
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders